Loading...
Please wait, while we are loading the content...
Similar Documents
Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Camerini, Andrea Valsuani, Chiara Mazzoni, Francesca Siclari, Olimpia Puccetti, Cheti Donati, Simone Rondini, Marianna Tartarelli, Gianna Puccinelli, Paolo Costanzo, Francesco Di Amoroso, Domenico |
| Copyright Year | 2010 |
| Abstract | BACKGROUND Elderly patients with advanced non-small-cell lung cancer (NSCLC) with poor performance status (PS) are a special population requiring particular attention. Single-agent oral vinorelbine could be an attractive option. PATIENTS AND METHODS A total of 43 patients with stage IIIB-IV NSCLC and Eastern Cooperative Oncology Group (ECOG) PS of two or more with good functional status were prospectively recruited. Oral vinorelbine was administered at the dose of 60 mg/m(2) on days 1-8 every 3 weeks. Primary end points were response rate and safety. RESULTS Overall response rate was 18.6% with 8 partial responses; 18 of 43 (41.8%) experienced stable disease lasting >12 weeks and 17 of 43 (39.6%) disease progression for an overall clinical benefit of 60.4%. Median time to progression was 4.0 (range 2-22) months and median overall survival 8.0 (range 3-35) months. Treatment was well tolerated. Of 187 cycles, we did not observe any grade 3/4 toxicity with the exception of a single not-febrile G3 neutropenia. Regardless of severity, main toxic effects observed were nausea in 48.1% and vomiting in 22.9% of patients, anemia in 43.2%, fatigue in 32.6% and leukopenia in 23.2%. CONCLUSION Single-agent oral vinorelbine is extremely safe in elderly patients with advanced NSCLC and ECOG PS of two or more and may represent a valid option in this very special population. |
| Starting Page | 1 |
| Ending Page | 23 |
| Page Count | 23 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/annonc/21/6/10.1093/annonc/mdp525/2/mdp525.pdf?Expires=1492904230&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q&Signature=eSZ12sn0jyNTe9OtTkVA92NbJpmJz0sk4YnzL4ctsy1m3HyJxC0cHUNlBBpG6~8FOsjyMdTadgjvTC56LJGYF4BD1gKPPUgNsmeeUHsh6El~QW8KpCJGD6eDEjIL5pBDPhRCvhENwBkM9BsUkN7U0g2TCMLr96d9rPU02qXYW2-1MyK3sNz3lBUoywJzGvSHkcTg3JJ3TZPvDdgkR8BL5HKNr9Jt2CXM--e9Mz7LLrQOxPcsa0XI~C3m2IXzSPOoxw3WmsGkpOdUl1ZrzC0-jlRdhWm8snsY2BYYDSDNuINJZtrAP8~FeUmiPGhw-9S0DkB4ZQeklS4pRMFxLeUymg__ |
| PubMed reference number | 19914959v1 |
| Alternate Webpage(s) | https://doi.org/10.1093/annonc/mdp525 |
| DOI | 10.1093/annonc/mdp525 |
| Journal | Annals of oncology : official journal of the European Society for Medical Oncology |
| Volume Number | 21 |
| Issue Number | 6 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Adverse reaction to drug Anemia Carcinoma of lung Eastern Cooperative Oncology Group Fatigue Fever Leukopenia Nausea Neutropenia Non-Small Cell Lung Carcinoma Overall Survival Paget's Disease, Mammary Patients Progressive Disease Vomiting performance status stage II bladder cancer vinorelbine |
| Content Type | Text |
| Resource Type | Article |
